X0202 SCHEDULE 13G/A 0001493152-25-029834 0002077247 XXXXXXXX LIVE 1 Common Stock, $0.001 par value 03/31/2026 0001750149 Inhibikase Therapeutics, Inc. 45719W205 1000 N. West Street, Suite 1200 Wilmington DE 19801 Rule 13d-1(c) Trails Edge Capital Partners, LP DE 8057345.00 0.00 8057345.00 0.00 8057345.00 N 6.1 IA PN See Item 4 for additional information. Trails Edge Biotechnology Master Fund, LP E9 8057345.00 0.00 8057345.00 0.00 8057345.00 N 6.1 PN See Item 4 for additional information. Ortav Yehudai X1 8057345.00 0.00 8057345.00 0.00 8057345.00 N 6.1 IN See Item 4 for additional information. Inhibikase Therapeutics, Inc. 1000 N. West Street, Suite 1200 This report on Schedule 13G/A (as amended, this "Schedule 13G") is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers". The address for each Filer is 3455 Peachtree Road NE, 5th Floor, Atlanta, GA 30326. See Item 4 of the cover page of each Filer. Y As of March 31, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 8,057,345 shares of Common Stock, par value $0.001 per share (the "Shares"), of Inhibikase Therapeutics, Inc. (the "Issuer"). The 8,057,345 Shares reported as beneficially owned on this Schedule 13G by each Filer consists of 8,057,345 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns 6.1% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 6.1% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on 132,032,636 Shares reported as issued and outstanding in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on March 26, 2026. 6.1 % 8,057,345.00 0.00 8,057,345.00 0.00 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 1 - Joint Filing Agreement, dated as of December 31, 2025, by and between Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on December 31, 2025). Trails Edge Capital Partners, LP Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai 05/15/2026 Trails Edge Biotechnology Master Fund, LP Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai 05/15/2026 Ortav Yehudai /s/ Ortav Yehudai 05/15/2026